Expanded Access to ABBV-CLS-484

NCT06188975 | Unknown

• 1 other identifier: C24-918
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-CLS-484 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Conditions

Advanced Solid Tumor Cancer

Interventions

DRUG: ABBV-CLS-484 DRUG

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

Sponsors & Collaborators

• Calico Life Sciences LLC: lead

MeSH Terms

Interventions

osunprotafib

Central Study Contacts

ABBVIE CALL CENTER

CONTACT

847.283.8955; abbvieclinicaltrials@abbvie.com

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 18, 2023
• First Posted: January 3, 2024
• Last Updated: January 3, 2024

Record last verified: 2023-12